BoneScalpel® To Be Showcased at EUROSPINE 2016 Hands-On Workshop

FARMINGDALE, N.Y., Oct. 5, 2016 /PRNewswire/ -- Misonix, Inc. (NASDAQ: MSON), an international surgical device company that designs, manufactures and markets innovative therapeutic ultrasonic products for spine surgery, neurosurgery, wound debridement, skull based surgery, laparoscopic surgery and other surgical applications, announced its plans to participate in the Spine Society of Europe ("EUROSPINE") Annual Congress 2016 to be held in Berlin, Germany on October 5-7, 2016.

Misonix will be exhibiting at EUROSPINE 2016 and will host a BoneScalpel hands-on workshop with a global audience of up to 50 spine surgeons on October 5^th.  The workshop entitled, Ultrasonic Techniques in Complex Spine will be facilitated by Fabrice Külling, MD, Deputy Chief of Spinal Surgery, Orthopedics and Traumatology from Kantonsspital in St. Gallen, Switzerland. The special workshop will provide surgeon attendees hands-on experience with the BoneScalpel ultrasonic bone-cutting instrument. They will learn how this technology can safely treat a wide variety of complex spine procedures. EUROSPINE 2016 is expected to draw more than 2,000 health professionals including doctors and spine surgeons from around the world who will gather to exchange information on the latest surgical challenges, treatment options, and treatment outcomes, as well as interact with colleagues.

"Misonix is very pleased to be able to participate in EUROSPINE as this presents a special opportunity to engage a very large, worldwide audience of premier spine surgeons who will have an opportunity to experience the BoneScalpel first-hand and the benefits of its ultrasound technology," said Stavros Vizirgianakis, Interim CEO of Misonix. 

BoneScalpel with ultrasonic technology is increasingly being adopted by the spinal surgeon community for the purpose of making precise and safe bone cuts during challenging spine surgeries. Common surgical applications successfully treated with BoneScalpel have included deformity cases, laminectomies and transforaminal lumbar interbody fusions ("TLIF") all of which has helped lead to its increased adoption. 

"We are excited about the opportunity to showcase BoneScalpel to some of the foremost spine surgeons in the world today," said Scott Ludecker, Senior Vice President of Global Sales and Marketing. "BoneScalpel's ability to mitigate the potential for soft tissue collateral damage and minimize blood loss during complex spine surgeries are universally understood as being cornerstones for providing better patient outcomes. These are among the attributes that continue to attract the spinal surgeon community to the BoneScalpel."

About Misonix
Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices.  Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $1.5 billion annually; Misonix's proprietary ultrasonic medical devices are used in spine surgery, neurosurgery, orthopedic surgery, wound debridement, cosmetic surgery, laparoscopic surgery, and other surgical and medical applications.  Additional information is available on the Company's website at www.misonix.com.

Safe Harbor Statement
With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.

Logo - http://photos.prnewswire.com/prnh/20160201/328020LOGO  

SOURCE Misonix, Inc.

Related Links

http://www.misonix.com